Cargando…
Targets of immunotherapy for hepatocellular carcinoma: An update
Hepatocellular carcinoma, the most common primary liver cancer, in an immunogenic tumor with a poor prognosis because these tumors are diagnosed at late stages. Although, surgical resection, ablation, liver transplant, and locoregional therapies are available for early stages; however, there are yet...
Autores principales: | Rai, Vikrant, Mukherjee, Sandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790386/ https://www.ncbi.nlm.nih.gov/pubmed/35126844 http://dx.doi.org/10.4254/wjh.v14.i1.140 |
Ejemplares similares
-
Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
por: Contratto, Merly, et al.
Publicado: (2018) -
Immunotherapy for recurrent hepatocellular carcinoma
por: Bhatt, Ahan, et al.
Publicado: (2023) -
Update on hepatocellular carcinoma: Pathologists’ review
por: El Jabbour, Tony, et al.
Publicado: (2019) -
Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
por: Chen, Pu, et al.
Publicado: (2021) -
Pathologic and molecular features of hepatocellular carcinoma: An update
por: Vij, Mukul, et al.
Publicado: (2021)